Genentech: Matthew Volgraf | Principal Scientist (Chemistry), Discovery Chemistry

Scientists / Our Scientists

"I’m motivated by the opportunity to work with talented colleagues on the toughest scientific problems."

Years at Genentech

Publications at Genentech

Awards & Honors

I joined Genentech in 2010 after completing my PhD at UC Berkeley with Prof. Dirk Trauner, followed by a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center with Prof. David Gin. My academic background in chemical biology and natural product total synthesis prepared me for the collaborative, multi-disciplinary team environment which is central to Genentech’s culture.

Featured Publication

Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design.

J Med Chem. 2016 Mar 24;59(6):2760-79.

Volgraf M, Sellers BD, Jiang Y, Wu G, Ly CQ, Villemure E, Pastor RM, Yuen PW1, Lu A, Luo X, Liu M, Zhang S, Sun L, Fu Y, Lupardus PJ, Wallweber HJ, Liederer BM, Deshmukh G, Plise E, Tay S, Reynen P, Herrington J, Gustafson A, Liu Y, Dirksen A, Dietz MG, Liu Y, Wang TM, Hanson JE, Hackos D, Scearce-Levie K, Schwarz JB.

View Abstract

My current role in the Discovery Chemistry department has been focused on developing small molecule drugs targeting ion channels within the neuroscience and immunology therapeutic areas. I am interested in studying the principles of drug design targeting membrane-bound enzymes and receptors, together with the physicochemical rules governing blood-brain barrier penetration.

Ligand binding at the protein–lipid interface: strategic considerations for drug design

Nature Reviews Drug Discovery, ISSN: 14741784 14741776

Jian Payandeh; Matthew Volgraf

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Matthew Volgraf

Principal Scientist (Chemistry), Discovery Chemistry

Featured Publication

Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design.